Flexion Therapeutics Inc. (NASDAQ:FLXN) shot up 6.1% on Wednesday . The company traded as high as $17.03 and last traded at $16.50, with a volume of 356,227 shares changing hands. The stock had previously closed at $15.55.

A number of brokerages have recently weighed in on FLXN. Cantor Fitzgerald reiterated a “buy” rating on shares of Flexion Therapeutics in a report on Thursday, May 26th. Janney Montgomery Scott reiterated a “buy” rating and issued a $30.00 price target on shares of Flexion Therapeutics in a report on Friday, July 1st. Wells Fargo & Co. reiterated a “buy” rating on shares of Flexion Therapeutics in a report on Thursday, June 30th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of Flexion Therapeutics in a report on Monday, April 4th. Finally, Vetr upgraded Flexion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $15.50 price target for the company in a report on Monday, June 13th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $31.81.

The firm’s market capitalization is $350.30 million. The stock has a 50-day moving average price of $14.03 and a 200 day moving average price of $12.81.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.17. Equities research analysts expect that Flexion Therapeutics Inc. will post ($2.84) earnings per share for the current fiscal year.

In other news, Director Samuel D. Colella purchased 25,504 shares of the business’s stock in a transaction on Tuesday, June 21st. The stock was purchased at an average price of $13.71 per share, with a total value of $349,659.84. Following the acquisition, the director now directly owns 3,435 shares in the company, valued at approximately $47,093.85. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Samuel D. Colella purchased 6,778 shares of the business’s stock in a transaction on Monday, June 20th. The stock was purchased at an average cost of $13.84 per share, with a total value of $93,807.52. Following the acquisition, the director now owns 3,435 shares in the company, valued at $47,540.40. The disclosure for this purchase can be found here.

Other institutional investors have recently bought and sold shares of the company. Oxford Asset Management purchased a new position in Flexion Therapeutics during the fourth quarter valued at approximately $1,901,000. Wells Fargo & Company MN boosted its position in shares of Flexion Therapeutics by 16.2% in the fourth quarter. Wells Fargo & Company MN now owns 430,545 shares of the specialty pharmaceutical company’s stock worth $8,296,000 after buying an additional 59,866 shares during the last quarter. Schroder Investment Management Group boosted its position in shares of Flexion Therapeutics by 21.0% in the fourth quarter. Schroder Investment Management Group now owns 470,200 shares of the specialty pharmaceutical company’s stock worth $9,061,000 after buying an additional 81,500 shares during the last quarter. Jennison Associates boosted its position in shares of Flexion Therapeutics by 35.1% in the third quarter. Jennison Associates now owns 2,831,268 shares of the specialty pharmaceutical company’s stock worth $42,073,000 after buying an additional 736,261 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Flexion Therapeutics by 2.7% in the fourth quarter. Jennison Associates LLC now owns 2,907,755 shares of the specialty pharmaceutical company’s stock worth $56,032,000 after buying an additional 76,487 shares during the last quarter.

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.